Literature DB >> 24842165

A Salmonella Typhimurium mutant strain capable of RNAi delivery: higher tumor-targeting and lower toxicity.

Xiawei Cheng1, Xiaoxin Zhang1, Yuqiang Zhou1, Chunmei Zhang1, Zi-Chun Hua2.   

Abstract

Bacteria are highly versatile and useful tools that could deliver short interfering RNA. In this study, a phoP/phoQ double-deleted Salmonella Typhimurium named VNP(PhoP/Q(-)) based on the genetic background of VNP20009. The biological safety and function of VNP(PhoP/Q(-)) were also analyzed. Our study revealed the following results: (1) VNP(PhoP/Q(-)) exhibited lower titers in tumor-free livers and spleens than VNP20009, (2) The survival of VNP(PhoP/Q(-)) in macrophages and 4T1 tumor cells was significantly reduced compared with that of VNP20009, (3) The tumor-targeting ability of VNP(PhoP/Q(-)) was significantly enhanced compared with that of VNP20009, and the anticancer effects of VNP(pPhoP/Q(-)) and VNP20009 on tumor-bearing mice were similar, (4) VNP(PhoP/Q(-)) could release an shRNA-expressing plasmid and express the EGFP reporter gene in tumor tissue. Therefore, VNP(PhoP/Q(-)) exhibited a better safety level in tumor-free mice and elicited an anti-tumor effect on tumor-bearing mice. Moreover, VNP(PhoP/Q(-)) could release an shRNA-expressing plasmid into the cytoplasm of host cells to silence targeted genes.

Entities:  

Keywords:  PhoP/PhoQ gene; RNA interference; SalmonellaTyphimurium; anti-tumor; delivering system; safety; tumor-targeting

Mesh:

Substances:

Year:  2014        PMID: 24842165      PMCID: PMC4119074          DOI: 10.4161/cbt.29185

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  44 in total

1.  Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.

Authors:  C Clairmont; K C Lee; J Pike; M Ittensohn; K B Low; J Pawelek; D Bermudes; S M Brecher; D Margitich; J Turnier; Z Li; X Luo; I King; L M Zheng
Journal:  J Infect Dis       Date:  2000-06-05       Impact factor: 5.226

Review 2.  Delivery of RNA interference.

Authors:  Charles X Li; Amy Parker; Ellen Menocal; Shuanglin Xiang; Laura Borodyansky; Johannes H Fruehauf
Journal:  Cell Cycle       Date:  2006-09-15       Impact factor: 4.534

Review 3.  RNAi therapeutics: principles, prospects and challenges.

Authors:  Lars Aagaard; John J Rossi
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

4.  One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products.

Authors:  K A Datsenko; B L Wanner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

5.  Ribonuclease activity and RNA binding of recombinant human Dicer.

Authors:  Patrick Provost; David Dishart; Johanne Doucet; David Frendewey; Bengt Samuelsson; Olof Rådmark
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

6.  Antitumor effects of Stat3-siRNA and endostatin combined therapies, delivered by attenuated Salmonella, on orthotopically implanted hepatocarcinoma.

Authors:  Huijie Jia; Yang Li; Tiesuo Zhao; Xin Li; Jiadi Hu; Di Yin; Baofeng Guo; Dennis J Kopecko; Xuejian Zhao; Ling Zhang; De Qi Xu
Journal:  Cancer Immunol Immunother       Date:  2012-04-18       Impact factor: 6.968

7.  Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.

Authors:  John F Toso; Vee J Gill; Patrick Hwu; Francesco M Marincola; Nicholas P Restifo; Douglas J Schwartzentruber; Richard M Sherry; Suzanne L Topalian; James C Yang; Frida Stock; Linda J Freezer; Kathleen E Morton; Claudia Seipp; Leah Haworth; Sharon Mavroukakis; Donald White; Susan MacDonald; John Mao; Mario Sznol; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

8.  Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs.

Authors:  Ling Zhang; Lifang Gao; Lijuan Zhao; Baofeng Guo; Kun Ji; Yong Tian; Jinguo Wang; Hao Yu; Jiadi Hu; Dhananjaya V Kalvakolanu; Dennis J Kopecko; Xuejian Zhao; De-Qi Xu
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

9.  Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer.

Authors:  Ming Zhao; Jack Geller; Huaiyu Ma; Meng Yang; Sheldon Penman; Robert M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

Review 10.  Potentiality of small interfering RNAs (siRNA) as recent therapeutic targets for gene-silencing.

Authors:  Chiranjib Chakraborty
Journal:  Curr Drug Targets       Date:  2007-03       Impact factor: 3.465

View more
  9 in total

1.  Comparison of Anticancer Activities and Biosafety Between Salmonella enterica Serovar Typhimurium ΔppGpp and VNP20009 in a Murine Cancer Model.

Authors:  Xiaoqing Liu; Yanxia Guo; Yujie Sun; Yu Chen; Wenzhi Tan; Jung-Joon Min; Jin Hai Zheng
Journal:  Front Microbiol       Date:  2022-06-29       Impact factor: 6.064

2.  Suppression of pancreatic ductal adenocarcinoma growth by intratumoral delivery of attenuated Salmonella typhimurium using a dual fluorescent live tracking system.

Authors:  Sujin Zhou; Zhenggang Zhao; Yan Lin; Sijia Gong; Fanghong Li; Jinshun Pan; Xiaoxi Li; Zhuo Gao; Allan Z Zhao
Journal:  Cancer Biol Ther       Date:  2016-04-18       Impact factor: 4.742

3.  The genes slyA, STM3120 and htrA are required for the anticancer ability of VNP20009.

Authors:  Xiaoxin Zhang; Qiaoqiao Xu; Lirun Yang; Yueyang Lai; Zhuangzhuang Zhang; Chao Han; Chizhou Jiang; Jiahuang Li; Yixin Shi; Zi-Chun Hua
Journal:  Oncotarget       Date:  2016-12-06

4.  In vitro synergistic effect of amlodipine and imipenem on the expression of the AdeABC efflux pump in multidrug-resistant Acinetobacter baumannii.

Authors:  Chao Hu; Yujun Li; Ziwen Zhao; Shuquan Wei; Zhuxiang Zhao; Huiling Chen; Peilian Wu
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

5.  A SARS-CoV-2 oral vaccine development strategy based on the attenuated Salmonella type III secretion system.

Authors:  Leyang Wu; Lin Li; Xingpeng Yin; Chenyang Li; Wenjie Xin; Lina Liu; Zichun Hua
Journal:  J Appl Microbiol       Date:  2022-07-31       Impact factor: 4.059

Review 6.  Recombinant Attenuated Salmonella enterica as a Delivery System of Heterologous Molecules in Cancer Therapy.

Authors:  Elayne Irene Becerra-Báez; Sergio Enrique Meza-Toledo; Paola Muñoz-López; Luis Fernando Flores-Martínez; Karla Fraga-Pérez; Kevin Jorge Magaño-Bocanegra; Uriel Juárez-Hernández; Armando Alfredo Mateos-Chávez; Rosendo Luria-Pérez
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

7.  Macrophage-mediated tumor-targeted delivery of engineered Salmonella typhi murium VNP20009 in anti-PD1 therapy against melanoma.

Authors:  Leyang Wu; Lin Li; Shufeng Li; Lina Liu; Wenjie Xin; Chenyang Li; Xingpeng Yin; Xuebo Xu; Feifei Bao; Zichun Hua
Journal:  Acta Pharm Sin B       Date:  2022-05-14       Impact factor: 14.903

Review 8.  Strains, Mechanism, and Perspective: Salmonella-Based Cancer Therapy.

Authors:  Cheng-Zhi Wang; Robert A Kazmierczak; Abraham Eisenstark
Journal:  Int J Microbiol       Date:  2016-04-14

Review 9.  Bacteria-cancer interactions: bacteria-based cancer therapy.

Authors:  Mai Thi-Quynh Duong; Yeshan Qin; Sung-Hwan You; Jung-Joon Min
Journal:  Exp Mol Med       Date:  2019-12-11       Impact factor: 8.718

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.